Colorectal Cancer
Conditions
Keywords
stage II colon cancer
Brief summary
RATIONALE: Diagnostic procedures that look for micrometastases in lymph nodes removed during surgery for colon cancer may help doctors learn the extent of disease. PURPOSE: This phase I trial is studying lymph nodes in patients with stage II colon cancer.
Detailed description
OBJECTIVES: * Determine whether the immunohistochemical and molecular presence of micrometastases in ≥ 12 lymph nodes removed during en-bloc resection in patients with stage II colon cancer correlates with 3-year disease-free survival. * Evaluate the prognostic significance of molecular markers detected in the primary tumor and develop a microarray-based gene signature for stage II colon cancer. OUTLINE: This is a multicenter study. Tumor tissue and regional lymph node samples are collected during surgery for analysis of micrometastases and molecular markers by immunohistochemistry, qRT-PCR, MM qRT-PCR, qRDNA-PCR, and microarray profiling. Patients are followed up periodically for 4 years after surgery.
Interventions
GENETICRNA marker analysis of lymph node and primary tumors
GENETICmicroarray profiling of primary tumors
GENETICreverse transcriptase-polymerase chain reaction of lymph node specimens
OTHERdiagnostic laboratory RNA and DNA biomarker analysis of primary tumors
PROCEDUREregional lymph node dissection
OTHERlymph node staining for H&E and pancytokeratin IHC
Sponsors
National Cancer Institute (NCI)
Saint John's Cancer Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
All of the following inclusion criteria must be met in order for the subject to be eligible. 1. Subjects must have CC detected by proctosigmoidoscopy, flexible endoscopy, or gastrograffin/barium enema, with no evidence of distant metastases within 8 weeks of enrollment. 2. Subjects with CC must have a computerized tomography (CT; at a minimum - spiral (helical) CT with 5-mm contiguous reconstruction algorithms and adequate volume (based on site-specific protocols) of oral and intravenous contrast agents) of the abdomen and pelvis and a chest x-ray or CT of the chest per standard of care, within 8 weeks prior to enrollment to rule out distant metastases. Subjects with preoperative CT scans and testing showing non-specific or non-diagnostic (equivocal) abnormalities may be eligible pending intraoperative exploration. 3. Greater than 18 years of age 4. Subjects must have a performance status ≤ 2 on the ECOG/Zubrod scale. 5. Subject is able to give informed consent, and must be willing to be followed clinically or by phone/email/mail correspondence 6. Subject must have a life expectancy of greater than 5 years not including the disease/diagnosis of CC. 7. Subject must have clinical assessment conducted by phone unless patients follow up are part of the regular clinical visits.
Exclusion criteria
Any of the following criteria will exclude the subject from the study. 1. Subjects requiring emergent surgery (within 2 hours of presentation) to prevent a life-threatening situation or death such as those with a perforated colon, metabolically significant complete bowel obstruction or massive GI bleeding will be excluded. Subjects who do not require emergent surgery, such as those with occult bleeding or early or partial bowel obstruction will be permitted to enter. 2. Subjects with any history of Crohn's disease, chronic ulcerative colitis, or familial polyposis. 3. Discovery of distant metastases intra-operatively. 4. Subjects with history of another malignancy over the last three years (except for completely resected cervical, skin cancers or in-situ cancers - see Appendix B for a list of exempt cancers). 5. Pregnant and/or lactating women. Potentially childbearing subjects (pre-menopausal women) should undergo a pregnancy test within 7 days prior to surgery and after signing consent. Subjects found to be pregnant will be ineligible and withdrawn from the study. 6. Subjects should not be participating in another research protocol at the time of enrollment. Participation during follow-up is acceptable. 7. Systemic chemotherapy for node negative colon cancer. 8. Complete polypectomy by endoscopy 9. Less than 12 lymph nodes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (time to local or distant recurrence after resection) | 48 months | The event to be used for DFS is time to recurrence (local or distant) after resection of colon cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (time to death from colorectal cancer) | 48 months | The event to be used for DFS is time to death after resection of colon cancer |
Countries
United States
Outcome results
None listed